Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocet, Docetaxel, and Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00250874Phase 2Unknown
- Sponsor
- Zeneus Pharma Ltd.
- Start
- Dec 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in breast cancer, sponsored by Zeneus Pharma Ltd. Primary endpoint: Maximum Tolerated Dose. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00250874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250874.